Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
95% of athletes are diagnosed and treated for non-invasive heart disease, such as heart attacks or seizures, or implantable cardioverter defibrillator (ICD) shock.
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]
Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.
1.
Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic
2.
Ignoring Colonoscopy Advice; Dry Mouth Acupuncture; Inflamed Tongue, Then Cancer.
3.
New imaging probe helps track prostate cancer and possibly treat it before resistance develops
4.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
5.
A protein with new anticancer activity has been identified
1.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
2.
Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology
3.
Exploring The Causes and Consequences of Low Transferrin Saturation
4.
Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post
5.
Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge